MedTrace Logo

Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

NCT03613129 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-05-12

Study results available
· View outcomes & findings →

Summary

This study seeks to investigate the safety, tolerability and efficacy of CT38, an experimental peptide administered by subcutaneous infusion, in the treatment of ME/CFS patients.

Conditions

  • Myalgic Encephalomyelitis
  • Chronic Fatigue Syndrome

Interventions

DRUG

CT38

Infusion

Sponsors & Collaborators

  • LUCINDA BATEMAN, MD

    lead OTHER

Principal Investigators

  • Lucinda Bateman, MD · Bateman Horne Center

  • Suzanne D Vernon, PhD · Bateman Horne Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2019-04-30
Completion
2019-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03613129 on ClinicalTrials.gov